Bristol-Myers Squibb Posts New Data on Pharmacodynamics, Safety, and Pharmacokinetics of Investigational Compound BMS-663068 for the Treatment of HIV-1 Infection
2011-02-28 · Bristol-Myers Squibb · original bms.com ↗
PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE: BMY) today posted to the company website an overview of new, phase IIa data on the pharmacodynamics, safety, and pharmacokinetics of a small molecule antiviral in development for the treatment of HIV-1 infection – BMS-663068, an HIV-1 attachment inhibitor. The data were presented today at the 18 th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews . Bristol-Myers SquibbMedia:Cristi Barnett, [email protected]:John Elicker, [email protected]
The release as fetched from its publisher. bms.com ↗